[Biochemical basis for using proteolysis inhibitors in inflammatory processes of the cornea].
D000222:Adaptation, Physiological / Q000187:drug effects; D000818:Animals; D007611:Aprotinin / Q000627:therapeutic use; D004341:Drug Evaluation; D004353:Drug Evaluation, Preclinical; D006801:Humans; D007635:Keratitis, Dendritic / Q000188:drug therapy* / Q000201:enzymology; D011480:Protease Inhibitors / Q000627:therapeutic use*; D011817:Rabbits; D013666:Tears / Q000201:enzymology; D014361:Trypsin Inhibitors / Q000627:therapeutic use; D000515:alpha 1-Antitrypsin / Q000378:metabolism; D000511:alpha-Macroglobulins / Q000378:metabolism
D011480:Protease Inhibitors; D014361:Trypsin Inhibitors; D000515:alpha 1-Antitrypsin; D000511:alpha-Macroglobulins; C011475:gordox; D007611:Aprotinin
Biokhimicheskoe obosnovanie k primeneniiu ingibitorov proteoliza pri vospalitel'nykh protsessakh v rogovitse.